US 11,707,503 B2
Modulators of complement activity
Michelle Denise Hoarty, Billerica, MA (US); Ketki Ashok Dhamnaskar, Foster City, CA (US); Daniel Elbaum, Newton, MA (US); Kristopher Josephson, San Carlos, CA (US); Kelley Cronin Larson, Quincy, MA (US); Zhong Ma, Lexington, MA (US); Nathan Ezekiel Nims, Winchester, MA (US); Alonso Ricardo, Winchester, MA (US); Kathleen Seyb, Wakefield, MA (US); Guo-Qing Tang, Acton, MA (US); Douglas A. Treco, Arlington, MA (US); Zhaolin Wang, Wellesley, MA (US); Ping Ye, Lexington, MA (US); Hong Zheng, New York, NY (US); and Sarah Jacqueline Perlmutter, Urbana, IL (US)
Assigned to Ra Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Ra Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Jan. 7, 2021, as Appl. No. 17/143,232.
Application 17/143,232 is a continuation of application No. 16/776,551, filed on Jan. 30, 2020, granted, now 10,918,691.
Application 16/776,551 is a continuation of application No. 16/393,393, filed on Apr. 24, 2019, granted, now 10,588,936, issued on Mar. 17, 2020.
Application 16/393,393 is a continuation of application No. 15/905,158, filed on Feb. 26, 2018, granted, now 10,328,115, issued on Jun. 25, 2019.
Application 15/905,158 is a continuation of application No. 15/547,085, granted, now 9,937,222, issued on Apr. 10, 2018, previously published as PCT/US2016/015412, filed on Jan. 28, 2016.
Claims priority of provisional application 62/185,298, filed on Jun. 26, 2015.
Claims priority of provisional application 62/108,772, filed on Jan. 28, 2015.
Claims priority of application No. PCT/US2015/035473 (WO), filed on Jun. 12, 2015.
Prior Publication US 2021/0283212 A1, Sep. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/10 (2006.01); A61K 39/00 (2006.01); C07K 16/36 (2006.01)
CPC A61K 38/10 (2013.01) [A61K 39/00 (2013.01); C07K 16/36 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A polypeptide of the formula R1-Xaa0-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-R2 (SEQ ID NO: 212), wherein:
a. R1 is absent or an acetyl group;
b. Xaa0 is absent or selected from the group consisting of norvaline and Ala;
c. Xaa1 is Cys;
d. Xaa2 is phenylglycine;
e. Xaa3 is Thr;
f. Xaa4 is selected from 7-azatryptophan and Trp;
g. Xaa5 is Glu;
h. Xaa6 is selected from the group consisting of Tyr, Phe, 4-fluorophenylalanine, and O-methyl-tyrosine;
i. Xaa7 is selected from the group consisting of Pro, N-methyl-serine, and N-methyl-alanine;
j. Xaa8 is selected from the group consisting of His and Ala;
k. Xaa9 is Cys;
l. Xaa10 is absent or selected from the group consisting of norvaline, and Ala;
m. Xaa11 is absent or Pro;
n. Xaa12 is absent or is norvaline; and
o. R2 is absent or —NH2.